Early Intervention vs Conservative Management in Severe Asymptomatic Aortic Stenosis: A Critical Review of Randomized Evidence

Aortic stenosis (AS) is a progressive disease that may remain asymptomatic despite underlying myocardial damage. Management of asymptomatic severe AS remains controversial, especially in the current era of safer surgical and transcatheter valve replacement. This critical review examines 4 randomized controlled trials—AVATAR (Aortic Valve Replacement Vs Conservative Treatment in Asymptomatic Severe Aortic Stenosis), RECOVERY (Randomized Comparison of Early Surgery vs Conventional Treatment in Very Severe Aortic Stenosis), EARLY TAVR (Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis), and EVOLVED (Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis)—comparing early aortic valve replacement with conservative management. While early intervention reduces composite endpoints involving heart failure hospitalization, individual trials have not demonstrated consistent mortality or stroke benefits. Importantly, sudden cardiac death was rare across all trials, and close surveillance appeared to be a key determinant of outcomes in the conservative arms. Differences in surveillance intensity, trial populations, and valve types limit pooled interpretations. Current evidence supports a tailored approach: conservative management is reasonable when reliable follow-up can be ensured, while early aortic valve replacement may benefit selected patients. Ongoing trials will help clarify long-term outcomes, optimal timing, and risk stratification strategies in asymptomatic AS.